Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clinical study
Pancreatology · 2024
DOI: 10.1016/j.pan.2024.03.012 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pancreatology, 2024. Verfasst von Suguru Yamada und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Nagoya Central Hospital, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Commissariat à l'Énergie Atomique et aux Énergies Alternatives.
Abstract (Originalsprache)
PURPOSE: We investigated true indication of neoadjuvant therapy (NAT) in resectable pancreatic cancer and the optimal surgical timing in borderline resectable pancreatic cancer. METHODS: A total of 687 patients with resectable or borderline resectable pancreatic cancer were enrolled. Survival analysis was performed by intention-to-treat analysis and propensity score matching (PSM) was conducted. RESULTS: In resectable disease, the NAT group showed better overall survival (OS) compared with the upfront group. Multivariate analysis identified CA19-9 level (≥100 U/mL) and lymph node metastasis to be prognostic factors, and a tumor size of 25 mm was the optimal cut-off value to predict lymph node metastasis. There was no significant survival difference between patients with a tumor size ≤25 mm and CA19-9 < 100 U/mL and those in the NAT group. In borderline resectable disease, OS in the NAT group was significantly better than that in the upfront group. CEA (≥5 ng/mL) and CA19-9 (≥100 U/mL) were identified as prognostic factors; however, the OS of patients fulfilling these factors was worse than that of the NAT group. CONCLUSIONS: NAT could be unnecessary in patients with tumor size ≤25 mm and CA19-9 < 100 U/mL in resectable disease. In borderline resectable disease, surgery should be delayed until tumor marker levels are well controlled.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Nagoya Central Hospital, Japan.
- Department of Surgery, Kansai Medical University, Japan.
- Biostatistics Center, Graduate School of Medicine, Kurume University, Japan.
- Division of Surgical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Department of Surgery, Kansai Medical University, Japan; Division of Surgical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: satoi@hirakata.kmu.ac.jp.
Förderung
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives
Zitieren
APA
Yamada, S., Hashimoto, D., Yamamoto, T., Yamaki, S., Oshima, K., Murotani, K., Sekimoto, M., Nakao, A., & Satoi, S. (2024). Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clinical study. Pancreatology. https://doi.org/10.1016/j.pan.2024.03.012
Vancouver
Yamada S, Hashimoto D, Yamamoto T, Yamaki S, Oshima K, Murotani K, et al. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clinical study. Pancreatology. 2024. doi:10.1016/j.pan.2024.03.012
BibTeX
@article{Yamada2024,
author = {Yamada, Suguru and Hashimoto, Daisuke and Yamamoto, Tomohisa and Yamaki, So and Oshima, Kenji and Murotani, Kenta and Sekimoto, Mitsugu and Nakao, Akimasa and Satoi, Sohei},
title = {Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clinical study},
journal = {Pancreatology},
year = {2024},
doi = {10.1016/j.pan.2024.03.012}
}
EUVIMED